(Q37273675)

19 August 2017

1 reference

title

Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood (English)

1 reference

19 August 2017

0 references

0 references

0 references

Anders Lönneborg

1

1 reference

19 August 2017

publication date

1 January 2008

1 reference

Molecular Diagnosis and Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

12

1 reference

19 August 2017

issue

5

1 reference

19 August 2017

page(s)

307-320

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Alzheimer Disease in the US Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Worldwide prevalence and incidence of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Disease-modifying therapies for Alzheimer disease: challenges to early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Amyloidosis and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

The role of biomarkers in clinical trials for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Biological markers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Biomarkers in the diagnosis of Alzheimer's disease: are we ready?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Both total and phosphorylated tau are increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

CSF biomarkers for mild cognitive impairment and early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Strategies for disease modification in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Paired helical filament antigen in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Mitochondrial involvement in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Lipid peroxidation in aging brain and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Mechanisms of free radical oxidation of unsaturated lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Increased CSF F2-isoprostane concentration in probable AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

A sandwich enzyme immunoassay for measuring AD7C-NTP as an Alzheimer's disease marker: AD7C test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Practical utility of urinary assay in the diagnosis of Alzheimer's disease: AlzheimAlert

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Biomarkers of Alzheimer disease in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Altered amyloid protein processing in platelets of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Platelet APP isoform ratios correlate with declining cognition in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

High cholesterol affects platelet APP processing in controls and in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Alzheimer disease-related abnormalities of amyloid beta precursor protein isoforms in the platelet: the brain's delegate in the periphery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Inflammation and therapeutic vaccination in CNS diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Circulating cytokines in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Proteome-based plasma biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Clinical biomarkers in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Evaluating the comparability of gene expression in blood and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

The future of genomic profiling of neurological diseases using blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Lymphocytes as a neural probe: potential for studying psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Evaluation of DNA microarray results with quantitative gene expression platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Gene expression profile analysis of lymphocytes from Alzheimer's patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Transcriptional profiling of Alzheimer blood mononuclear cells by microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Diagnostic accuracy of Alzheimer's disease: a clinicopathological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Diagnostic accuracy of Alzheimer's disease: a neuropathological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Research evaluation and prospective diagnosis of dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Neuropathology of cognitively normal elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Increased cerebrospinal fluid cAMP levels in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Clinical proteomics in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Detection of amyloid beta protein precursor immunoreactivity in normal and Alzheimer's disease cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Immunochemical Properties of Ubiquitin Conjugates in the Paired Helical Filaments of Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Tau Protein in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256296

Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection.

21 January 2018

1 reference

12 December 2020

Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage

1 reference

12 December 2020

Plasma levels of amyloid beta proteins did not differ between subjects taking statins and those not taking statins

1 reference

12 December 2020

The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process

1 reference

12 December 2020

Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease.

1 reference

12 December 2020

Advances on biological markers in early diagnosis of Alzheimer disease.

1 reference

12 December 2020

Elevated levels of tau and ubiquitin in brain and cerebrospinal fluid in Alzheimer's disease.

1 reference

12 December 2020

Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT.

1 reference

12 December 2020

Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

1 reference

12 December 2020

Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease?

1 reference

12 December 2020

Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group

1 reference

12 December 2020

Acetylcholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type

1 reference

12 December 2020

1 reference

12 December 2020

Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity

1 reference

12 December 2020

Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.

1 reference

12 December 2020

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

12 December 2020

Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression

1 reference

12 December 2020

Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries.

1 reference

12 December 2020

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.

1 reference

12 December 2020

Serum cytokine levels in patients with Alzheimer's disease

1 reference

12 December 2020

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

1 reference

12 December 2020

Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231.

1 reference

12 December 2020

Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type

1 reference

12 December 2020

CSF markers for incipient Alzheimer's disease

1 reference

12 December 2020

Philothermal response of polymorphonuclear leukocytes in dementia of the Alzheimer type

1 reference

12 December 2020

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

1 reference

12 December 2020

Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.

1 reference

12 December 2020

Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.

1 reference

12 December 2020

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

12 December 2020

Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk

1 reference

12 December 2020

Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction

1 reference

12 December 2020

Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease.

1 reference

12 December 2020

Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients

1 reference

12 December 2020

Combination of serum markers related to several mechanisms in Alzheimer's disease

1 reference

12 December 2020

Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease

1 reference

12 December 2020

Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia.

1 reference

12 December 2020

17beta-estradiol reduces plasma Abeta40 for HRT-naïve postmenopausal women with Alzheimer disease: a preliminary study

1 reference

12 December 2020

Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques

1 reference

12 December 2020

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

1 reference

12 December 2020

Biological markers in Alzheimer's disease

1 reference

12 December 2020

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

1 reference

12 December 2020

Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256296

1 reference

19 August 2017

1 reference